
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increased further by Week 24, with gene analysis showing intestinal repair and tissue remodeling unique to ABBV-466. The study involved 300 patients with moderate to severe Crohn's disease, many of whom had failed prior advanced treatments, reflecting real-world complexity. Safety profiles were comparable across treatments. These results highlight ABBV-466's potential as a more effective treatment option and will be presented at the 2026 United European Gastroenterology Week Congress.
AbbVie's promising new therapy ABBV-466 for Crohn's disease adds to the company's innovative pipeline. On Pluang, AbbVie Inc (ABBV) shares trade at USD 285.00, near its 52-week high of USD 285.42, with a slight 0.15% decrease as of Oct 19, 2026 15:11 WIB. The stock's market cap stands at $504.37 billion, reflecting strong investor interest in its health sector advancements.